Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,126Revenue $M49.0Net Margin (%)12.2Z-Score10.2
Enterprise Value $M1,106EPS $0.6Operating Margin %29.2F-Score6
P/E(ttm))156Cash Flow Per Share $0.6Pre-tax Margin (%)11.2Higher ROA y-yN
Price/Book17.410-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales21.55-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow32.1y-y EBITDA Growth Rate %39.0ROA % (ttm)5.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)8ROE % (ttm)12.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M20.8ROI % (ttm)10.2Gross Margin Increase y-yN

Gurus Latest Trades with LGND

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 53.33-18%New holding, 55492 sh.55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 53.33-18%New holding, 36908 sh.36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 53.33-20%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 53.332%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 53.3318%New holding, 6136 sh.6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 53.33318%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 53.33305%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 53.33406%Add 110.73%705,016
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 53.33406%New holding, 10000 sh.10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 53.33342%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 53.33228%New holding, 26900 sh.26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LGND Ken Fisher 2014-06-3036,9080.180New Buy
LGND Joel Greenblatt 2014-06-3055,4920.270.04New Buy
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KOZARICH JOHN WDirector 2014-10-15Buy2,000$45.6816.75view
FOEHR MATTHEW WEVP and COO 2014-10-10Buy85$44.9118.75view
KNOTT DAVID MDirector 2014-10-09Buy4,000$43.0123.99view
Sabba Stephen LDirector 2014-10-09Buy2,000$43.1223.68view
Aryeh JasonDirector 2014-10-09Buy11,000$42.9924.05view
HIGGINS JOHN LPresident & CEO 2014-08-15Buy1,000$54.97-2.98view
FOEHR MATTHEW WEVP and COO 2014-06-30Buy428$43.7921.79view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-06-30Buy329$43.7921.79view
Herman Melanie JDirector of Accounting 2014-06-30Buy98$43.7921.79view
Herman Melanie JDirector of Accounting 2014-06-09Sell1,100$69.68-23.46view

Press Releases about LGND :

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 


More From Other Websites
Twitter gives out 47% of its revenue in stock bonuses Oct 29 2014
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss Oct 29 2014
Ligand Reports Third Quarter 2014 Financial Results Oct 27 2014
Ambaraella, Pier One, Pfizer, Teva Pharmaceutical and Ligand Pharmaceuticals highlighted as Zacks... Oct 27 2014
Ligand beats Street 3Q forecasts Oct 27 2014
Ligand beats Street 3Q forecasts Oct 27 2014
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 27 2014
8:04 am Ligand Pharma reports EPS in-line, misses on revs; guides Q4 EPS below consensus, revs... Oct 27 2014
Ligand Reports Third Quarter 2014 Financial Results Oct 27 2014
Q3 2014 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open Oct 27 2014
Ligand to Report Third Quarter 2014 Financial Results Oct 27 2014
Will Ligand Pharmaceuticals Beat Q3 Earnings Estimates? Oct 24 2014
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? Oct 24 2014
Ligand (LGND) Shares March Higher, Can It Continue? Oct 24 2014
Why Earnings Season Could Be Great for Ligand (LGND) Oct 24 2014
Cubist Pharmaceuticals' Q3 Earnings Beat Expectations Oct 23 2014
Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing Oct 22 2014
The Zacks Analyst Blog Highlights: Pacific Biosciences of California, Teva Pharmaceutical... Oct 22 2014
Orexigen (OREX) Shows Strength: Stock Gains 11.1% Oct 22 2014
Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? Oct 21 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK